Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Barbara Ann Karmanos Cancer Center

4100 John R, Detroit, MI 48201

Our Mission

The Karmanos Cancer Center is a unique, integrated center of research, patient care and education, dedicated to the prevention, early detection, treatment and eventual eradication of cancer.

Who We Are

Karmanos is based in southeast Michigan, in midtown Detroit, and is one of 47 National Cancer Institute-designated Comprehensive Cancer Centers in the United States. In fact, Karmanos is the only hospital in Michigan dedicated exclusively to fighting cancer.

Caring for approximately 12,000 new patients annually and conducting more than 800 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation’s best cancer centers. Karmanos offers access to more than 90 cancer treatments often not available elsewhere in Michigan.

Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate cancer. Our long-term partnership with the Wayne State University School of Medicine enhances the collaboration of critical research and academics related to cancer care.

Why Choose Karmanos

We work with hundreds of doctors to arrange for convenient care for patients and families. Together, our cancer teams and your doctor can recommend the best treatment options with immediate access to the latest cancer-fighting drugs and therapies. At Karmanos we’ll make sure your first chance at beating cancer is your best chance toward a future free of cancer.

Website: Barbara Ann Karmanos Cancer Center

Contact:
800-527-6266

Trials at this location:

HCRN LUN15-299

Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma: Hoosier Cancer Research Network LUN15-299

Status: Open to Accrual
Read More

HCRN GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Closed to Accrual
Read More

HCRN GU15-262

Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Status: Closed to Accrual
Read More